Clinical trials: Levodopa
Healthy Participants
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
The purpose of this study is to learn how plants can play a role in gain/loss of sodium in the urine and in the regulation of blood pressure.
- Trial name
- NCT01064739
- Testing
- Fava beans, Fixed Sodium Diet
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Parkinson Disease
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
- Trial name
- NCT04513340
- Testing
- WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- Where
- India
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Parkinson Disease, Medication
Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD
In this project, patients with Parkinson's Disease (PD) will be characterized by measuring cognitive and motor function and relation to effect of Levodopa.
- Conditions
- Parkinson Disease, Medication, UPDRS, Motor Function
- Trial name
- NCT06275633
- Testing
- Levodopa
- Where
- Denmark
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Retinal Diseases
Effect of Levodopa on Human Multifocal Electroretinogram
It is known that dopamine is a functional neuromodulator at several levels of the visual system. Dopamine seems to be involved in the organization of the ganglion cell and the bipolar cell receptive fields and modulation of…
- Trial name
- NCT00812760
- Testing
- levodopa
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healhty
A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy…
- Trial name
- NCT07442591
- Testing
- Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Volunteers
Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers
A group of 24 healthy volunteers receive one tablet of an association of levodopa 200 mg and benserazide 50 mg corresponding to two drug products: a test formulation (Evoser ®; Phoenix S.A.I.C.
- Trial name
- PHOE10903 (NCT01327261)
- Testing
- Levodopa + benserazide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires
Parkinson Disease
How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
This study has two purposes: 1) to understand the effect of a decline of dopamine in the brain during normal aging and in patients with Parkinson's disease, and 2) to investigate how medicines used to treat Parkinson's disease…
- Trial name
- NCT00040196
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Visual Attention in Parkinson's Disease
Visual Selective Attention in Parkinson's Disease
Parkinson's disease (PD), which is generally considered to be a motor disorder, is now known to be accompanied in many instances by a variety of cognitive defects.
- Trial name
- VSA-PD (NCT01135407)
- Testing
- Recording during computerized tests
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Idiopathic Parkinson's Disease
Dopamine Effect on Inhibitory Control
The effect of Levodopa medication on inhibitory control in Parkinson's patients is extremely debated despite the fact that this has potential clinical and therapeutic implications.
- Trial name
- DEI (NCT03665493)
- Testing
- PD patients H&Y=1.5-2 Medications ON, PD patients H&Y=1.5-2 Medications OFF, Healthy age-matched controls
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Giovanni Mirabella
Parkinson's Disease
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg…
- Trial name
- NCT02763852
- Testing
- BIA 3-202, Madopar® 125
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cerebrovascular Accident, Aphasia
Dopaminergic Enhancement of Learning and Memory in Aphasia
The purpose of this study is to determine whether levodopa, in combination with a high frequency language training, is effective in boosting naming performance in patients with aphasia.
- Trial name
- NCT00102869
- Testing
- levodopa
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Cocaine Dependence
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient…
- Trial name
- COST (NCT01468012)
- Testing
- levodopa carbidopa and entacapone (LCE)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Parkinson's Disease
Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and therefore the levodopa area-under-the-concentration-curve values, half-life, and trough concentrations The study will help determining…
- Trial name
- NCT01103011
- Testing
- ND0611
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Dyskinesias, Movement Disorders
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa.
- Conditions
- Dyskinesias, Movement Disorders, Parkinson Disease
- Trial name
- NCT00467597
- Testing
- Levodopa (delivered intravenously)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Healthy
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
The purpose of this study is to assess the safety and bioequivalence of a single oral dose of carbidopa+levodopa+entacapone combination versus a single oral dose of carbidopa+levodopa combination plus a single oral dose of…
- Trial name
- NCT00415740
- Testing
- ELC200 (carbidopa+levodopa+entacapone)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis
Parkinson's Disease
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg…
- Trial name
- NCT02763839
- Testing
- BIA 3-202, Sinemet 25/100
- Where
- Portugal
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Effect of Levodopa on Postural Motor Learning in Parkinson Disease
The primary goal of this project is to gain a better understanding of whether and how levodopa (a common anti-Parkinson disease medication) alters postural motor learning in people with Parkinson disease.
- Trial name
- NCT02239978
- Testing
- Postural perturbation
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development